P2RY12 and acute coronary syndrome: The 2017 European Society of Cardiology STEMI guidelines and 2020 European Society of Cardiology non-ST-segment elevation acute coronary syndrome guidelines recommend the clinical application of a potent P2Y12 inhibitor (i.e., ticagrelor or prasugrel) for AMI patients who have undergone PCI (1, 10).